MTOR and systemic lupus erythematosus: Mechanistic target of rapamycin (mTOR) is proved to be notably activated in the immune system in SLE patients.[3] The mTOR inhibitor sirolimus (also called rapamycin) is reported to be effective in adult SLE with few side effects.